| Sales | 6,846a | 7,065a |
| Of which revenue from non-core activities | 283a | 231a |
| Of which net sales | 6,563a | 6,834a |
| Cost of goods sold | -4,627a | -4,690a |
| Gross profit | 2,219a | 2,375a |
| Commercial costs | -308a | -296a |
| Administrative costs | -697a | -521a |
| Research and development costs | -342a | -339a |
| Other operating gains and (losses) | -161a | -141a |
| Earnings from associates and joint ventures | 21a | 25a |
| Results from portfolio management and major restructuring | -243a | -388a |
| Results from legacy remediation and major litigations | -18a | -168a |
| EBIT | 471a | 547a |
| Cost of borrowings | -113a | -190a |
| Interest on loans and short term deposits | 22a | 81a |
| Other gains and (losses) on net indebtedness | -4a | -31a |
| Cost of discounting provisions | -18a | -28a |
| Result from equity instruments measured at fair value | -7a | 10a |
| Profit/(loss) for the year before taxes | 352a | 389a |
| Income taxes | -357a | -192a |
| Profit/(loss) for the year | -5a | 197a |
| Attributable to | — | — |
| Syensqo share | -5a | 193a |
| Non-controlling interests | 0a | 3a |
| Net sales | 6,563a | 6,834a |
| Revenue from non-core activities | 283a | 231a |
| Raw materials, utilities and consumables used | -2,940a | -2,931a |
| Changes in inventories | 8a | -114a |
| Personnel expenses | -1,525a | -1,591a |
| Wages and direct social benefits | -1,175a | -1,219a |
| Employer's contribution for social insurance | -270a | -276a |
| Pensions and insurance benefits | -59a | -74a |
| Other personnel expenses | -20a | -22a |
| Depreciation, amortization and impairments | -732a | -739a |
| Other variable logistics expenses | -209a | -181a |
| Other fixed expenses | -823a | -605a |
| Addition and reversal of provisions (excluding employee benefit obligations) | -92a | -387a |
| Income from cross indemnities, PFAS insurance indemnities, energy hedging novation and Edison partial award | 0a | 213a |
| M&A costs and gains and losses on disposals | -83a | -208a |
| Earnings from associates and joint ventures | 21a | 25a |
| EBIT | 471a | 547a |